DIAMOND
DEAD

Serial Number

97220299

Owner

VESALIUS THERAPEUTICS INC.

Attorney

Christina M. Licursi

Filing Date

Jan 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DIAMOND Trademark

Serial Number: 97220299

DIAMOND is a trademark filed by VESALIUS THERAPEUTICS INC. on January 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

VESALIUS THERAPEUTICS INC. (4 trademarks)

CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

January 14, 2022

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders

Software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for data analysis in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks; software for genetic assessment and identification of cancer, diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific research, namely, research and analysis services featuring artificial intelligence and machine learning analytics in the fields of healthcare, biomedical and genomic research; research and development in the field of drug discovery and development, computational biology, bioinformatics, and genomics; research and development of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; technical scientific consultation and product development for others in the fields of drug discovery and development, pharmaceuticals, biotechnology and immunology; consulting in the fields of drug discovery and development, clinical trial management and patient engagement in drug clinical trials

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 3, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Apr 1, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 1, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 14, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 17, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 8, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 8, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 8, 2022 CNRT
ASSIGNED TO EXAMINER
Jul 5, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 21, 2022 NWOS